Nasdaq
$1.00▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $141.4MShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 3d agoAfter-hours26.10.22 05:104Ownership#●●●
Veraxa Biotech AG - Post de-SPAC
Insider Ziegler Christoph Samuel has filed a Form 4 to report changes in beneficial ownership of securities for Veraxa Biotech AG as of October 20, 2026. This filing formalizes the insider's equity position updates.…more
$1.00+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 05:106-KKey event
Veraxa Biotech AG - Post de-SPAC
Veraxa Biotech presented in vivo proof-of-concept data for its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The data demonstrated significant tumor volume reduction in a xenograft breast cancer model at a single 3 mg/kg dose, confirming the platform's potential for improved safety compared to conventional ADCs.…more
$1.00+0.00%vs prev closeView filingShare - 9.14After-hours26.09.15 05:103Ownership
Veraxa Biotech AG - Post de-SPAC
Insider Willener Raju Sudir of Veraxa Biotech AG has filed a Form 3, reporting their initial statement of beneficial ownership of company securities. This filing serves as the official disclosure of the insider's stock holdings.…more
$1.00+0.00%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:00#●●●#●●●
VERAXA Biotech Presents In Vivo Proof-of-Concept Data for BiTAC-ADC Technology…more
VERAXA Biotech presented in vivo data demonstrating the anti-tumor efficacy and selective activation of its BiTAC-ADC technology platform. This represents an early-stage research milestone, and the technology requires further validation through clinical development.…more
$1.00+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.7Pre-market26.10.07 20:06
●●●●●●●● ●●●●● ●●●●●●
VERAXA announced that its lead T cell engager successfully killed tumor cells across ten patient-derived lung cancer models in preclinical testing. This remains an early-stage development, requiring further clinical validation to determine therapeutic efficacy.…more
$1.00+0.00%vs prev closeShareBenzinga - 10.7Pre-market26.10.07 20:00
●●●●●●●● ●●●●● ●●●●●●
VERAXA Biotech announced the implementation of FDA-aligned New Approach Methodologies to reduce animal testing and potentially accelerate its preclinical R&D pipeline. As this update focuses on research methodology rather than clinical milestones or financial results, it is considered a neutral development.…more
$1.00+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report